Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Regorafenib, and Iparomlimab/Tuvonralimab in Advanced Colorectal Cancer
NCT06930118Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, iparomlimab + tuvonralimab in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Started Apr 2025; status: recruiting.
02
Drugs
tucidinostatiparomlimab + tuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06930118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930118.